NAMS Certified Menopause Practitioner (NCMP) Exam Prep
2026/2027 | 300+ Practice Questions & Answers
Question 1
According to The Menopause Society (formerly NAMS) clinical
guidelines, what is the preferred initial management strategy for a
healthy 52-year-old woman with bothersome moderate-to-severe
vasomotor symptoms and an intact uterus?
• A. Systemic estrogen-progestogen therapy
• B. High-dose oral progestin-only therapy
• C. Compounded bioidentical hormone therapy pellets
• D. High-dose testosterone replacement therapy
Correct Answer: A. Systemic estrogen-progestogen therapy
Detailed Rationale: For women with an intact uterus, systemic estrogen
requires a progestogen to prevent endometrial hyperplasia. FDA-
approved standard hormone therapy is preferred over compounded
bioidentical hormones due to established safety profiles, purity, and
quality control.
Question 2
Prasterone (intravaginal dehydroepiandrosterone - DHEA) is approved
for the treatment of moderate-to-severe dyspareunia due to
menopause. What is its primary mechanism of action?
• A. It acts as an irreversible aromatase inhibitor in breast tissue.
, • B. It is converted intracrinologically into active estrogens and
androgens within the vaginal cells.
• C. It binds directly to systemic FSH receptors to suppress
gonadotropins.
• D. It stimulates hepatic synthesis of sex hormone-binding globulin.
Correct Answer: B. It is converted intracrinologically into active
estrogens and androgens within the vaginal cells.
Detailed Rationale: Intravaginal prasterone relies on intracrinology,
where target vaginal cells metabolize DHEA locally into active androgens
and estrogens without significantly elevating serum sex steroid levels.
Question 3
Which of the following baseline assessments is mandatory before
initiating systemic menopausal hormone therapy in a patient with an
intact uterus presenting with abnormal uterine bleeding?
• A. Endometrial tissue evaluation (biopsy or transvaginal
ultrasound)
• B. Serum CA-125 tumor marker assay
• C. Diagnostic hysterosalpingography
• D. Complete hormonal panel including inhibin B and AMH
Correct Answer: A. Endometrial tissue evaluation (biopsy or
transvaginal ultrasound)
Detailed Rationale: Any abnormal uterine bleeding must be evaluated
to rule out endometrial hyperplasia or carcinoma prior to or concurrent
with starting systemic menopausal hormone therapy.
,Question 4
What is the primary mechanism of action of flibanserin, an FDA-
approved medication for hypoactive sexual desire disorder (HSDD)?
• A. Serotonin 5-HT1A receptor agonist and 5-HT2A receptor
antagonist
• B. Selective dopamine D2 receptor agonist
• C. Peripheral phosphodiesterase-5 inhibitor
• D. Gamma-aminobutyric acid type B agonist
Correct Answer: A. Serotonin 5-HT1A receptor agonist and 5-HT2A
receptor antagonist
Detailed Rationale: Flibanserin acts centrally as a serotonin 5-HT1A
agonist and 5-HT2A antagonist, decreasing inhibitory serotonin tone
while increasing dopamine and norepinephrine transmission to improve
sexual desire.
Question 5
When counseling a patient about the risk of venous thromboembolism
(VTE) associated with menopausal hormone therapy, which of the
following patient characteristics confers the highest baseline VTE risk
independent of MHT?
• A. Advanced age and obesity (BMI ≥ 30 kg/m²)
• B. Mild essential hypertension controlled with a single agent
• C. Occasional social alcohol consumption
• D. History of well-controlled hypothyroidism
, Correct Answer: A. Advanced age and obesity (BMI ≥ 30 kg/m²)
Detailed Rationale: Obesity and advancing age are major independent
risk factors for venous thromboembolism, which compounds the
incremental VTE risk when oral estrogen therapy is introduced.
Question 6
A 56-year-old postmenopausal woman with a history of breast cancer 4
years ago presents with severe, refractory genitourinary syndrome of
menopause (GSM) symptoms that have failed non-hormonal
moisturizers. After consultation with her oncologist, low-dose vaginal
estrogen is considered. What best describes the systemic absorption
profile of ultra-low-dose vaginal estrogen tablets (e.g., 10 mcg
estradiol)?
• A. It causes systemic estrogen levels to spike significantly higher
than premenopausal peak levels.
• B. It results in minimal systemic absorption, keeping serum
estradiol levels well within the postmenopausal range.
• C. It is metabolized entirely in the skin before reaching target
organs.
• D. It permanently shuts down adrenal steroidogenesis.
Correct Answer: B. It results in minimal systemic absorption, keeping
serum estradiol levels well within the postmenopausal range.
Detailed Rationale: Low-dose vaginal estrogen formulations (such as 10
mcg estradiol tablets) provide direct local relief while maintaining
serum estradiol levels within normal postmenopausal ranges,
minimizing systemic exposure.
2026/2027 | 300+ Practice Questions & Answers
Question 1
According to The Menopause Society (formerly NAMS) clinical
guidelines, what is the preferred initial management strategy for a
healthy 52-year-old woman with bothersome moderate-to-severe
vasomotor symptoms and an intact uterus?
• A. Systemic estrogen-progestogen therapy
• B. High-dose oral progestin-only therapy
• C. Compounded bioidentical hormone therapy pellets
• D. High-dose testosterone replacement therapy
Correct Answer: A. Systemic estrogen-progestogen therapy
Detailed Rationale: For women with an intact uterus, systemic estrogen
requires a progestogen to prevent endometrial hyperplasia. FDA-
approved standard hormone therapy is preferred over compounded
bioidentical hormones due to established safety profiles, purity, and
quality control.
Question 2
Prasterone (intravaginal dehydroepiandrosterone - DHEA) is approved
for the treatment of moderate-to-severe dyspareunia due to
menopause. What is its primary mechanism of action?
• A. It acts as an irreversible aromatase inhibitor in breast tissue.
, • B. It is converted intracrinologically into active estrogens and
androgens within the vaginal cells.
• C. It binds directly to systemic FSH receptors to suppress
gonadotropins.
• D. It stimulates hepatic synthesis of sex hormone-binding globulin.
Correct Answer: B. It is converted intracrinologically into active
estrogens and androgens within the vaginal cells.
Detailed Rationale: Intravaginal prasterone relies on intracrinology,
where target vaginal cells metabolize DHEA locally into active androgens
and estrogens without significantly elevating serum sex steroid levels.
Question 3
Which of the following baseline assessments is mandatory before
initiating systemic menopausal hormone therapy in a patient with an
intact uterus presenting with abnormal uterine bleeding?
• A. Endometrial tissue evaluation (biopsy or transvaginal
ultrasound)
• B. Serum CA-125 tumor marker assay
• C. Diagnostic hysterosalpingography
• D. Complete hormonal panel including inhibin B and AMH
Correct Answer: A. Endometrial tissue evaluation (biopsy or
transvaginal ultrasound)
Detailed Rationale: Any abnormal uterine bleeding must be evaluated
to rule out endometrial hyperplasia or carcinoma prior to or concurrent
with starting systemic menopausal hormone therapy.
,Question 4
What is the primary mechanism of action of flibanserin, an FDA-
approved medication for hypoactive sexual desire disorder (HSDD)?
• A. Serotonin 5-HT1A receptor agonist and 5-HT2A receptor
antagonist
• B. Selective dopamine D2 receptor agonist
• C. Peripheral phosphodiesterase-5 inhibitor
• D. Gamma-aminobutyric acid type B agonist
Correct Answer: A. Serotonin 5-HT1A receptor agonist and 5-HT2A
receptor antagonist
Detailed Rationale: Flibanserin acts centrally as a serotonin 5-HT1A
agonist and 5-HT2A antagonist, decreasing inhibitory serotonin tone
while increasing dopamine and norepinephrine transmission to improve
sexual desire.
Question 5
When counseling a patient about the risk of venous thromboembolism
(VTE) associated with menopausal hormone therapy, which of the
following patient characteristics confers the highest baseline VTE risk
independent of MHT?
• A. Advanced age and obesity (BMI ≥ 30 kg/m²)
• B. Mild essential hypertension controlled with a single agent
• C. Occasional social alcohol consumption
• D. History of well-controlled hypothyroidism
, Correct Answer: A. Advanced age and obesity (BMI ≥ 30 kg/m²)
Detailed Rationale: Obesity and advancing age are major independent
risk factors for venous thromboembolism, which compounds the
incremental VTE risk when oral estrogen therapy is introduced.
Question 6
A 56-year-old postmenopausal woman with a history of breast cancer 4
years ago presents with severe, refractory genitourinary syndrome of
menopause (GSM) symptoms that have failed non-hormonal
moisturizers. After consultation with her oncologist, low-dose vaginal
estrogen is considered. What best describes the systemic absorption
profile of ultra-low-dose vaginal estrogen tablets (e.g., 10 mcg
estradiol)?
• A. It causes systemic estrogen levels to spike significantly higher
than premenopausal peak levels.
• B. It results in minimal systemic absorption, keeping serum
estradiol levels well within the postmenopausal range.
• C. It is metabolized entirely in the skin before reaching target
organs.
• D. It permanently shuts down adrenal steroidogenesis.
Correct Answer: B. It results in minimal systemic absorption, keeping
serum estradiol levels well within the postmenopausal range.
Detailed Rationale: Low-dose vaginal estrogen formulations (such as 10
mcg estradiol tablets) provide direct local relief while maintaining
serum estradiol levels within normal postmenopausal ranges,
minimizing systemic exposure.
